Category Archives: Pharmaceutical and Biological Industry

GlaxoSmithKline (China) involved in criminal bribery case

Consolidated Report by According to the Ministry of Public Security of the People’s Republic of China, recently, the Ministry of Public Security through unified actions in Changsha, Shanghai and Zhengzhou and other places identified that some executives of GlaxoSmithKline (China) InvestmentCo.Ltd, or GSK are suspected of serious economic crimes and legal investigation has been raised.
Public security organs have identified that in recent years, GlaxoSmithKline (China) Investment Co., Ltd. in order expand the sale channels in China has adopted methods including raising drug prices, the use of travel agencies, making direct bribery or other forms of sponsorship to individual government officials, pharmaceutical industry associations and hospitals and doctors. Meanwhile, fabricated VAT invoices issued by travel agencies are adopted by the company in committing criminal activities.
In addition, the public security organs have identified that some executives of GlaxoSmithKline (China) Investment Co., are suspected of taking rebates, commissions and other forms of taking bribes.
Currently, the public security organs have adopted criminal compulsory actions against relevant suspects of GlaxoSmithKline (China) Investment Co., Ltd. and related travel agencies according to the law. After initial interrogation, the suspects have made confession to the crimes. The case is still under further investigation .

51 global recalls by Johnson & Johnson since 2005: suspected “double standards” in China

Johnson & Johnson is engaged in a dozen fields including medicine, health care, medical diagnostics, medical devices and personal care products, consumer goods and so on. In the Chinese market, its brands include Tylenol, Bondi, Merrill Lynch, Zyrtec, Risperdal, domperidone, Miconazole, Triatop, Neutrogena, Clean & Clear, Listerine mouthwash and dozens of well-known brands. In 2012, Johnson & Johnson was ranked as No. 138 of the world’s top 500 with operating revenue of US $65 billion.